Navigation Links
Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
Date:9/21/2009

entation, subgroup analyses from the SPIRIT III trial demonstrated evidence of the strong performance by XIENCE V in a variety of patients and lesion types that represent complex patients. In patients with diabetes, the analysis showed there was no difference at three years in MACE between XIENCE V and TAXUS (11.0 percent for XIENCE V vs. 10.3 percent in TAXUS)*** . In fact, XIENCE V maintained a consistent rate of clinical events after the first year (8.7 percent MACE at one year and 11.0 percent MACE at three years), whereas TAXUS demonstrated a sustained upward trend in clinical events from one year to three years (4.7 percent MACE at one year and 10.3 percent MACE at three years). In patients without diabetes, the MACE rate for TAXUS at three years was more than double the MACE rate for XIENCE V at three years (9.1 percent for XIENCE V vs. 18.7 percent for TAXUS).

"The SPIRIT III data clearly show that XIENCE V performs in a consistent manner, with clinical benefits continuing to improve over time compared to TAXUS," said Robert Hance, senior vice president, vascular, Abbott. "We are pleased to begin this year's TCT conference with a strong showing of data for Abbott's market-leading XIENCE V, and look forward to presenting the highly anticipated SPIRIT IV one-year results later this week, which should provide physicians with additional valuable insights."

One-year results from the company's SPIRIT IV trial will be presented on Wednesday, Sept. 23, during the first late-breaking clinical trials session of the TCT conference. The SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents, with 3,690 patients enrolled, including more than 1,000 patients with diabetes. The study results will provide valuable information about the efficacy and safety of XIENCE V compared to TAXUS. The SPIRIT III trial was not designed to analyze statistical differences in any of the patient subgroups, as th
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
4. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
5. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
10. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
11. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HOLLYWOOD, Calif. , March 27, 2015 ... of life of myeloma patients while working toward prevention ... Higgins (D-NY) for introducing a federal resolution (H. ... of March 2015 as "National Multiple Myeloma Awareness Month." ... living with myeloma worldwide, and more than 110,000 new ...
(Date:3/27/2015)... -- RnRMarketResearch.com adds "Visceral Pain - ... of 52 pages with latest updates, data and ... The report "Visceral Pain - Pipeline Review, H1 2015" ... Visceral Pain, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... 21, 2011  Watson Pharmaceuticals, Inc. (NYSE: WPI ... Paul Bisaro, Watson,s President and Chief Executive Officer, will ... at the 2011 Piper Jaffray Health Care Conference on ... the New York Palace Hotel in New York. The ...
... Ultragenyx Pharmaceutical, Inc., a biotechnology company focused on ... today announced that Tom Kassberg has joined the ... be responsible for leading the company,s business development ... the human resources and legal affairs functions. Mr. ...
Cached Medicine Technology:Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 2Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 3Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 4
(Date:3/29/2015)... (PRWEB) March 29, 2015 Youth Villages ... counties in Oregon to assess the feasibility of implementing ... emotional and behavioral problems and their families. , Third ... select participants that will be provided technical assistance throughout ... counties join six other national awardees chosen by Third ...
(Date:3/29/2015)... 2015 “Health is an endo thing, ... learn more about the cannabinoid system … we learn ... Publius’ Go Endo-Cannabinoid Update ~ new on the ... celebrated. Publius, of The Cannabis Papers: A citizen’s guide ... Health (PubMed) cannabinoid system (CS) articles discussing: cannabinoids in ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New York ... commemorated its three-year anniversary of being the only 24/7 ... 24-hour urgent care, Emergency Medical Care offers its clients ... Emergency Medical Care’s Urgent Care NYC services ... injuries, ear infections, fevers, insect bites, burns, animal bites, ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... with positive airway pressure (PAP) therapy improves a number ... from the The Children,s Hospital of Philadelphia. "In ... we observed significant improvements in neurobehavioral function after three ... Marcus, professor of pediatrics at the Children,s Hospital of ...
... , THURSDAY, Feb. 9 (HealthDay News) -- A growing ... plastic surgery from social networking sites rather than friends, ... in 2011 got information from social media such as Facebook ... in 2010. The number of patients who sought information from ...
... , THURSDAY, Feb. 9 (HealthDay News) -- Four new ... by researchers, who also pinpointed six independent diabetes-associated gene ... findings, from an analysis of 50,000 genetic variants across ... in the Feb. 9 issue of the American ...
... Wake Forest Baptist Medical Center researchers have again proven ... them with a quick, 30-second laser treatment can kill them. ... was published in 2009, but now they,ve taken the science ... initiating cancer stem cells. These stem cells are hard to ...
... This release is available in French . ... patients with advanced cancer suffer from cachexia, a condition ... weight loss, extreme fatigue and reduces quality of life. ... University Health Centre (MUHC) has found that patients with ...
... (HealthDay News) -- ,The longer Hispanic women live in the United ... a new study says. Researchers analyzed data from 2,141 Hispanic ... U.S. National Health and Nutrition Examination Survey 1999-2006. The study ... women who had lived in the United States for less than ...
Cached Medicine News:Health News:PAP therapy improves neurobehavioral outcomes in children with OSA 2Health News:More Patients Seek Plastic Surgery Advice From Facebook, Twitter 2Health News:4 New Genes Linked to Type 2 Diabetes 2Health News:Nanotube therapy takes aim at breast cancer stem cells 2Health News:Heavy lifting for cancer research 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: